Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Evaluation of Alirocumab Versus Ezetimibe on Top of Statin in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia
- Conditions
- Hypercholesterolemia
- Interventions
- First Posted Date
- 2016-03-22
- Last Posted Date
- 2019-09-30
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 615
- Registration Number
- NCT02715726
- Locations
- 🇨🇳
Investigational Site Number 1560018, Beijing, China
🇨🇳Investigational Site Number 1560008, Hangzhou, China
🇨🇳Investigational Site Number 1560009, Shenyang, China
Postprandial Glucodynamic Response to Insulin Glargine/Lixisenatide Fixed Ratio Combination in Japanese Patients With Type 2 Diabetes Mellitus
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: PlaceboDrug: Insulin glargine HOE901
- First Posted Date
- 2016-03-18
- Last Posted Date
- 2020-06-16
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 20
- Registration Number
- NCT02713477
- Locations
- 🇯🇵
Investigational Site Number 392001, Fukuoka-Shi, Japan
A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Drug: HOE901-U300 (Insulin Glargine 300 U/ml)Drug: Mandated back ground therapy
- First Posted Date
- 2016-02-23
- Last Posted Date
- 2022-03-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 638
- Registration Number
- NCT02688933
- Locations
- 🇺🇸
Investigational Site Number 840-044, Los Angeles, California, United States
🇺🇸Investigational Site Number 840-040, Henderson, Nevada, United States
🇺🇸Investigational Site Number 840-019, Dallas, Texas, United States
Safety Study of Sargramostim in Treating Patients With Mild Cognitive Impairment Due to Alzheimer's Disease
- Conditions
- Dementia Alzheimer's Type
- Interventions
- First Posted Date
- 2016-01-29
- Last Posted Date
- 2017-04-07
- Lead Sponsor
- Sanofi
- Registration Number
- NCT02667496
- Locations
- 🇺🇸
Investigational Site Number 840001, Houston, Texas, United States
Study of Capecitabine and Cyclophosphamide Administered as a Single Pill in Patients With Advanced Breast Cancer
- Conditions
- Breast Cancer Metastatic
- Interventions
- First Posted Date
- 2016-01-26
- Last Posted Date
- 2018-02-01
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 2
- Registration Number
- NCT02664103
- Locations
- 🇮🇳
Investigational Site Number 356001, Vellore, India
🇮🇳Investigational Site Number 356009, Kollkata, India
🇮🇳Investigational Site Number 356002, Mumbai, India
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
- Conditions
- Dyslipidemia
- Interventions
- Drug: StatinsDrug: Antihyperglycemic Drug
- First Posted Date
- 2015-12-30
- Last Posted Date
- 2018-05-01
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 413
- Registration Number
- NCT02642159
- Locations
- 🇺🇸
Investigational Site Number 840-156, Tustin, California, United States
🇫🇮Investigational Site Number 246101, Oulu, Finland
🇺🇸Investigational Site Number 840-118, Los Angeles, California, United States
A Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of a Single Dose of SAR438544 in Comparison to Glucagon in Type 1 Diabetes Mellitus Patients Under Induced Hypoglycemia
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- First Posted Date
- 2015-12-18
- Last Posted Date
- 2016-09-02
- Lead Sponsor
- Sanofi
- Registration Number
- NCT02635243
A Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Doses of SAR438544 in Comparison to Placebo and Glucagon in Healthy Subjects and Type 1 Diabetes Mellitus Patients
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- First Posted Date
- 2015-12-09
- Last Posted Date
- 2016-08-23
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 20
- Registration Number
- NCT02625636
- Locations
- 🇺🇸
Investigational Site Number 840001, Chula Vista, California, United States
Treatment of Type 2 Diabetes With Long Acting Basal Insulin in Jordan
- First Posted Date
- 2015-11-17
- Last Posted Date
- 2018-10-12
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 242
- Registration Number
- NCT02606357
- Locations
- 🇯🇴
JORDAN, Jordan, Jordan
Assessment of the Safety of SAR342434 and Humalog® When Administered as Continuous Subcutaneous Insulin Infusion
- First Posted Date
- 2015-11-11
- Last Posted Date
- 2016-05-19
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 27
- Registration Number
- NCT02603510
- Locations
- 🇺🇸
Investigational Site Number 840002, Little Rock, Arkansas, United States
🇺🇸Investigational Site Number 840001, Denver, Colorado, United States